Form 4: Sensei Biotherapeutics Director Sells Shares

Sensei Biotherapeutics director James Peyer reported multiple sales of common stock totaling 21,295 shares in early December 2025.

Summary

• James Peyer, a Director and 10% owner of Sensei Biotherapeutics, Inc. (SNSE), reported multiple sales of common stock.
• The transactions occurred on December 4, 2025, and December 5, 2025.
• A total of 21,295 shares were sold across four separate transactions.
• The sales were executed at weighted average prices ranging from $9.06 to $13.16 per share.
• Following these transactions, Mr. Peyer's indirect beneficial ownership stands at 161,359 shares.
• The shares are held by Cambrian Biopharma Inc., where Mr. Peyer is CEO and may direct voting and disposition, though he disclaims beneficial ownership.
• The transactions were made pursuant to a Rule 10b5-1(c) plan.
• The amount of shares beneficially owned following the first reported transaction (177,654) reflects an adjustment for a 1-for-20 stock split effectuated by the issuer.

Sentiment

Score: 6

Explanation: While insider selling can be viewed negatively, the disclosure that these transactions were made pursuant to a Rule 10b5-1(c) plan suggests they were pre-arranged and not indicative of new, adverse material information, mitigating the negative sentiment.

Positives

• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating pre-scheduled sales not based on new, non-public information.

Negatives

• Insider selling by a director and 10% owner, even if pre-planned, can sometimes be perceived negatively by the market.
• A significant number of shares (21,295) were sold.

Risks

• No specific risks are detailed in this Form 4 beyond the general market perception of insider selling.

Future Outlook

No forward-looking statements or guidance are provided in this insider transaction report.

Management Comments

• Mr. Peyer disclaims beneficial ownership of such shares.

Industry Context

Insider transactions are common in the biotechnology sector, often related to liquidity needs or portfolio rebalancing, especially for early investors or founders. The use of 10b5-1 plans is a standard practice for insiders to manage stock sales while adhering to insider trading regulations.

Related Party Transactions

• The shares are held by Cambrian Biopharma Inc., where the reporting person, James Peyer, is the Chief Executive Officer and may direct the voting and disposition of shares. This represents an indirect beneficial ownership structure.

Stakeholder Impact

• Shareholders may interpret the insider selling, even if pre-planned, as a signal, potentially leading to short-term price volatility.

Key Dates

Recommendation

The insider sales, while significant in volume, were conducted under a Rule 10b5-1(c) plan, which typically indicates pre-scheduled transactions rather than a reaction to new, negative company developments. This mitigates the immediate negative signal often associated with insider selling. Without additional company-specific news or financial performance data, a 'hold' recommendation is appropriate, advising investors to monitor future developments.

Keywords

Sensei Biotherapeutics, SNSE, insider trading, Form 4, stock sale, James Peyer, Cambrian Biopharma, 10b5-1 plan